Market Cap : 1.41 B | Enterprise Value : 1.18 B | PE Ratio : At Loss | PB Ratio : 4.17 |
---|
NAS:ENTA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:ENTA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Enanta Pharmaceuticals has the GF Value Rank of 1.
The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.
GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).
We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.
After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
For the Biotechnology subindustry, Enanta Pharmaceuticals's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Enanta Pharmaceuticals's GF Value Rank distribution charts can be found below:
* The bar in red indicates where Enanta Pharmaceuticals's GF Value Rank falls into.
Thank you for viewing the detailed overview of Enanta Pharmaceuticals's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Russell Lesley | director | 41 MOORES RD. FRAZER PA 19355 |
Peterson Kristine | director | AMARIN CORPORATION MYSTIC PACKER BLDG., 12 ROOSEVELT AVENUE MYSTIC CT 06355 |
Foletta Mark G | director | AMYLIN PHARMACEUTICALS INC 9360 TOWNE CENTRE DR SAN DIEGO CA 92121 |
Hata Yujiro S | director | C/O XENCOR, INC. 111 WEST LEMON AVENUE MONROVIA CA 91016 |
Luu Brendan | officer: Sr. VP, Business Dev. | C/O ENANTA PHARMACEUTICALS, INC. 500 ARSENAL STREET WATERTOWN MA 02472 |
Kieffer Tara Lynn | officer: Sr. VP, New Product Dev. | C/O ENANTA PHARMACEUTICALS, INC. 500 ARSENAL STREET WATERTOWN MA 02472 |
Adda Nathalie | officer: Sr. VP & Chief Medical Officer | C/O ENANTA PHARMACEUTICALS, INC. 500 ARSENAL STREET WATERTOWN MA 02472 |
Gardiner Nathaniel S. | director | C/O ENANTA PHARMACEUTICALS, INC. 500 ARSENAL STREET WATERTOWN MA 02472 |
Golumbeski George | director | C/O CELGENE CORP. 86 MORRIS AVENUE SUMMIT NJ 07901 |
Ocain Tim | officer: Senior Vice President | C/O ENANTA PHARMACEUTICALS, INC. 500 ARSENAL STREET WATERTOWN MA 02472 |
Carter Bruce L A | director | C/O ZYMOGENETICS, INC. 1201 EASTLAKE AVENUE SEATTLE WA 98102 |
Saints Capital Granite, L.p. | 10 percent owner | 475 SANSOME STREET SUITE 1850 SAN FRANCISCO CA 94111 |
Saints Capital Granite, Llc | 10 percent owner | 475 SANSOME STREET, SUITE 1850 SAN FRANCISCO CA 94111 |
Obp (bermuda) Iii - Holdings Llc | 10 percent owner | 475 SANSOME STREET, SUITE 1850 SAN FRANCISCO CA 94111 |
Mrna - Holdings Llc | 10 percent owner | 475 SANSOME STREET, SUITE 1850 SAN FRANCISCO CA 94111 |
From GuruFocus
Other Sources
By Seekingalpha 2021-03-08
By Seekingalpha 2022-02-08
By Seekingalpha 2021-02-08
By Zacks 2022-02-08
By tipranks.com 2022-02-13
By Zacks 2022-02-07
By Zacks 2021-11-19
By Zacks 2021-11-03
By tipranks.com 2022-03-18
By Zacks 2021-11-04
By Zacks 2021-05-06